Table 4 CP-868,596 pharmacokinetic summary

From: Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

 

Pharmacokinetic parameters

Regimens

T max (h)

Cmax (ng ml–1)a

AUC(0–12) (h ng ml–1)b

CP-868,596 (100 mg BID fed)

N

13

13

13

 Mean

2.30

493

3200

 Median

1.75

419

2240

 CV%

64

86

96

CP-868,596 (100 mg BID fed)+docetaxel (75 mg m–2)

N

13

13

13

 Mean

2.98

360

2540

 Median

3

326

1640

 CV%

44

83

89

CP-868,596 (60 mg BID fed)+axitinib (5 mg BID fed)+docetaxel (75 mg m–2)

N

5

5

5

 Mean

4.4

137

760

 Median

1.75

129

654

 CV%

111

52

49

  1. Abbreviations: AUC=area under the curve; BID=twice daily.
  2. CV%=100% × (s.d./mean).
  3. aCmax: CP-868,596 vs CP-868,596 plus docetaxel: P=0.055.
  4. bAUCtau (0–12 h) CP-868,596 vs CP-868,596 plus docetaxel: P=0.117.